Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Solid Nanosuspensions: The Emerging Technology And Pharmaceutical Applications As Nanomedicine

S. Verma, D. Burgess
Published 2010 · Materials Science

Save to my Library
Download PDF
Analyze on Scholarcy
Share
One of the foremost reasons for such a widespread interest in nanosuspensions as drug delivery systems is their ability to provide formulations of poorly soluble drugs with increased saturation solubility and higher dissolution rates. Nanosuspensions manifest these properties because of their small size and high surface area. The unique properties of the nanosuspensions along with their fast development times, low production costs, ease of manufacture and scale-up as well as their ability to extend the lifecycle of off-patent drugs have resulted in rapid commercialization. Nanosuspensions provide us with a useful tool for formulating an ever-increasing number of poorly water soluble drugs in pharmaceutical development programs.
This paper references
10.1002/JPS.20366
Bioavailability enhancement of a COX-2 inhibitor, BMS-347070, from a nanocrystalline dispersion prepared by spray-drying.
S. Yin (2005)
Novel injectable formulations of insoluble drugs
S. Pace (1999)
10.1128/AAC.45.6.1771-1779.2001
Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis
N. Schöler (2001)
10.5860/choice.35-4499
Physical chemistry of surfaces
A. Adamson (1960)
10.1016/S0169-409X(00)00118-6
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)
10.1208/pt0803052
Monitoring ibuprofen release from multiparticulates: In situ fiber-optic technique versus the HPLC method: A technical note
Vishal Bijlani (2008)
10.1016/0378-5173(95)00122-Y
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
G. Liversidge (1995)
10.1002/JPS.2600690407
Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits.
R. Schoenwald (1980)
10.1201/9780849350610
Injectable dispersed systems : formulation, processing, and performance
D. Burgess (2005)
10.1023/A:1014276917363
Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration
C. Jacobs (2004)
10.1016/J.IJPHARM.2007.03.011
Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
M. Kassem (2007)
10.1016/J.EJPB.2005.05.009
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.
C. Keck (2006)
10.1016/J.EJPB.2006.05.008
Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
J. Hecq (2006)
10.1023/B:PHAM.0000029283.47643.9c
An Atomic Force Microscopy Study of the Effect of Nanoscale Contact Geometry and Surface Chemistry on the Adhesion of Pharmaceutical Particles
Jennifer C. Hooton (2004)
10.1016/0005-2736(94)90231-3
Liposome-complement interactions in rat serum: implications for liposome survival studies.
D. Devine (1994)
10.1016/J.ADDR.2006.09.011
Nanomedicine: developing smarter therapeutic and diagnostic modalities.
O. Farokhzad (2006)
10.1248/CPB.41.737
Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region.
N. Kondo (1993)
10.1208/aapsj060320
Particle size analysis: AAPS workshop report, cosponsored by the Food and Drug Administration and the United States Pharmacopeia
D. Burgess (2008)
10.1166/JNN.2007.449
Supercritical fluid processing of drug nanoparticles in stable suspension.
P. Pathak (2007)
10.1002/1521-4125(200206)25:6<657::AID-CEAT657>3.0.CO;2-5
Experimental Investigation into the Influence of Mixing on Nanoparticle Precipitation
H. Schwarzer (2002)
Nanoparticles for improving the dissolution and oral bioavailability of spironolactone, a poorly-soluble drug
M. H. El-Shabouri (2002)
10.1016/J.SUPFLU.2005.09.005
Formation and stabilization of ibuprofen nanoparticles in supercritical fluid processing
P. Pathak (2006)
10.1201/9781315274287
Principles of colloid and surface chemistry
P. C. Hiemenz (1977)
10.1201/9780203492918
Advanced Pharmaceutics: Physicochemical Principles
C. Kim (2004)
10.1248/BPB.16.796
Pharmacokinetics of a micronized, poorly water-soluble drug, HO-221, in experimental animals.
N. Kondo (1993)
10.1002/ADMA.200306466
Nanoparticle synthesis in engineered organic nanoscale reactors
D. Shchukin (2004)
10.1097/01.NAN.0000264712.26219.67
Liposomal drug delivery.
Allison Sd (2007)
10.1006/JCIS.1996.4647
Synthesis of Copper Nanoparticles in Nonionic Water-in-Oil Microemulsions
Qi (1997)
10.1002/JPS.2600750316
Effect of particle dissolution rate on ocular drug bioavailability.
H. W. Hui (1986)
10.1023/A:1011032328064
Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa
A. Lamprecht (2004)
10.1021/JS970331I
Characterization of submicron systems via optical methods.
R. Haskell (1998)
10.1211/0022357023691
Nanosuspensions: a promising drug delivery strategy
V. Patravale (2004)
10.1016/S0001-8686(97)00042-0
The effect of surface heterogeneities on colloidal forces
J. Walz (1998)
10.1208/pt040336
Assessing the accuracy of routine photon correlation spectroscopy analysis of heterogeneous size distributions
Christer B. Frantzen (2008)
10.1200/JCO.1990.8.7.1263
Hypersensitivity reactions from taxol.
R. Weiss (1990)
10.1016/S0378-5173(99)00085-X
An investigation into the distribution of lecithins in nanosuspension systems using low frequency dielectric spectroscopy.
K. Peters (1999)
10.1016/J.JPBA.2005.05.014
A new approach in the prediction of the dissolution behavior of suspended particles by means of their particle size distribution.
A. Tinke (2005)
10.1006/JCIS.1995.1064
Synthesis of Nanosize Silica in Aerosol OT Reverse Microemulsions
F. Arriagada (1995)
Hydrosols : alternatives for the parenteral application of poorly water soluble drugs
P. Gassmann (1994)
10.1016/S0378-5173(02)00686-5
Formulation of amphotericin B as nanosuspension for oral administration.
O. Kayser (2003)
10.1016/S0378-5173(01)00628-7
An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen.
G. J. Vergote (2001)
Book Review: Geotechnical Engineering Investigation Handbook, Second Edition , by Roy E. Hunt, Boca Raton, Florida: Taylor & Francis Group, LLP, 2005
R. Bert (2005)
10.1007/s11095-006-9174-3
Particle Engineering for Pulmonary Drug Delivery
Albert H. L. Chow (2006)
10.1016/S0378-5173(99)00411-1
Nanosuspensions of poorly soluble drugs--reproducibility of small scale production.
M. Grau (2000)
10.1016/0378-5173(95)00148-C
Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats
G. Liversidge (1995)
10.1016/S0378-5173(02)00154-0
A novel particle engineering technology: spray-freezing into liquid.
T. L. Rogers (2002)
10.1016/J.COPBIO.2007.01.006
Nanotechnological applications in medicine.
S. Caruthers (2007)
10.1016/0169-409X(95)00010-5
Ocular absorption following topical delivery
K. Jaervinen (1995)
10.1016/J.IJPHARM.2004.08.001
The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
Y. Wu (2004)
10.1016/J.JCONREL.2006.11.011
Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals.
M. T. Crisp (2007)
10.1023/A:1017920823963
Titanium Dioxide Nanoparticles Produced in Water-in-oil Emulsion
Y. Mori (2001)
10.1200/JCO.2005.08.002
Nanoparticle albumin-bound paclitaxel for metastatic breast cancer.
M. Harries (2005)
10.1016/S0939-6411(98)00038-1
Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats.
M. Roser (1998)
10.1016/J.IJPHARM.2006.01.008
Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.
P. Kocbek (2006)
10.1358/DOT.2006.42.9.1009902
Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer.
M. Pinder (2006)
10.1016/S0378-5173(03)00029-2
Preparation of griseofulvin nanoparticles from water-dilutable microemulsions.
M. Trotta (2003)
10.1081/PDT-120027417
Micron‐Size Drug Particles: Common and Novel Micronization Techniques
N. Rasenack (2004)
10.1021/JS980236P
General solution for diffusion-controlled dissolution of spherical particles. 1. Theory.
J. Wang (1999)
10.1038/nbt1006-1211
The emerging nanomedicine landscape
Volker Wagner (2006)
10.1166/JBN.2005.033
Pharmaceutical Aspects of Polymeric Nanoparticles for Oral Drug Delivery
V. Bhardwaj (2005)
10.1093/ANNONC/MDL104
Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.
M. Green (2006)
10.1007/s11095-006-9146-7
Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications
Boris Y. Shekunov (2006)
10.1016/0169-409X(95)00039-A
Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system
G. Storm (1995)
10.1016/S0939-6411(99)00049-1
An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization.
K. Ostrander (1999)
10.1093/JAC/45.1.77
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
K. Peters (2000)
10.2174/157341307780619251
Application of Nanoparticles in Oral Delivery of Immediate Release Formulations
F. Kesisoglou (2007)
10.1016/J.EJPB.2004.03.022
Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology.
J. Möschwitzer (2004)
10.1023/A:1019829622088
Effect of Nanonization on Absorption of 301029: Ex Vivo and In Vivo Pharmacokinetic Correlations Determined by Liquid Chromatography/Mass Spectrometry
L. Jia (2004)
10.1016/S0378-5173(02)00040-6
Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability.
R. Mueller (2002)
10.1016/J.IJPHARM.2006.08.005
Recrystallization of fluconazole using the supercritical antisolvent (SAS) process.
H. J. Park (2007)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1016/S0378-5173(02)00072-8
Enhanced drug dissolution using evaporative precipitation into aqueous solution.
Marazban Sarkari (2002)
10.1016/S0006-291X(75)80433-5
The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs.
R. Juliano (1975)
10.1016/S0378-5173(99)00434-2
Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against leishmania infected macrophages.
O. Kayser (2000)
10.1023/A:1022676709565
Characterization of Crystalline Drug Nanoparticles Using Atomic Force Microscopy and Complementary Techniques
H. Shi (2004)
10.1023/A:1020390422785
Improvement of Dissolution Rates of Poorly Water Soluble APIs Using Novel Spray Freezing into Liquid Technology
Jiahui Hu (2004)
10.1002/CEAT.200406111
High‐Pressure Homogenization as a Process for Emulsion Formation
S. Schultz (2004)
10.1016/J.EJPS.2004.12.010
Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion.
J. Lee (2005)
10.1021/LA9705266
Biomimetic Synthesis of Calcium Carbonate Particles in a Pseudovesicular Double Emulsion
Takayuki Hirai (1997)
10.1023/B:PHAM.0000048196.61887.e5
Development and Characterization of a Scalable Controlled Precipitation Process to Enhance the Dissolution of Poorly Water-Soluble Drugs
T. L. Rogers (2004)
10.1016/S0378-5173(00)00640-2
A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications.
O. Kayser (2001)
10.1023/A:1016085108889
Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size
M. P. Desai (2004)
10.1016/0378-5173(88)90235-9
Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions
M. Bisrat (1988)
10.1016/S0896-8446(01)00064-X
Particle design using supercritical fluids: Literature and patent survey
Jennifer Jung (2001)
Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue.
N. Wu (1993)
10.1016/J.IJPHARM.2007.02.030
Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat.
Barrett E. Rabinow (2007)
10.1093/TOXSCI/KFJ084
Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles.
P. Borm (2006)
10.1002/JPS.10039
General solution for diffusion-controlled dissolution of spherical particles. 2. Evaluation of experimental data.
J. Wang (2002)
10.1023/A:1021410028371
Dissolution Rate Enhancement by in Situ Micronization of Poorly Water-Soluble Drugs
N. Rasenack (2004)
10.1007/s11095-005-7781-z
Comparison of Diafiltration and Tangential Flow Filtration for Purification of Nanoparticle Suspensions
Gautam Dalwadi (2005)
10.1038/nrd1494
Nanosuspensions in drug delivery
Barrett E. Rabinow (2004)
10.1016/S0928-0987(02)00251-8
Nanosizing: a formulation approach for poorly-water-soluble compounds.
E. Merisko-Liversidge (2003)
10.1081/DIS-100107750
Precipitation and Condensation of Organic Particles
J. Texter (2001)
10.1007/s11095-005-4581-4
Formulating Paclitaxel in Nanoparticles Alters Its Disposition
Teng Kuang Yeh (2005)
10.1016/J.JCONREL.2005.11.013
Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.
Jun-ichi Jinno (2006)
10.1002/JPS.20822
PQRI recommendations on particle-size analysis of drug substances used in oral dosage forms.
Sharon M Snorek (2007)
10.1080/03639040600975147
Preparation of Azithromycin Nanosuspensions by High Pressure Homogenization and its Physicochemical Characteristics Studies
Dianrui Zhang (2007)
10.1038/233617B0
Mechanism of Oil Droplet Fragmentation in High Pressure Homogenizers
L. Phipps (1971)
10.1016/J.VIROL.2006.08.012
Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages.
Huanyu Dou (2007)
10.1016/S0168-3659(01)00432-1
Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions.
M. Trotta (2001)
10.1016/J.IJPHARM.2005.05.014
Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine.
J. Hecq (2005)
10.1016/J.IJPHARM.2004.07.019
The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs.
J. Kipp (2004)
10.1016/S0927-7757(97)00012-5
Preparation of monodisperse colloids of biologically active compounds 1. Naproxen
G. Pozarnsky (1997)
10.1016/J.FOODCHEM.2004.08.044
β-Carotene nanodispersions: preparation, characterization and stability evaluation
C. Tan (2005)
10.1021/AC00108A013
Particle size analysis
H. Barth (1985)
10.1007/s11095-005-8635-4
Nanoparticles of Poorly Water-Soluble Drugs Prepared by Supercritical Fluid Extraction of Emulsions
B. Shekunov (2005)
10.1021/LA00009A007
Synthesis, Characterization, and Properties of Microemulsion-Mediated Nanophase TiO2 Particles
V. Chhabra (1995)
10.1016/0378-5173(90)90228-V
Physicochemical aspects of drug release: X. Investigation of the applicability of the cube root law for characterization of the dissolution rate of fine particulate materials
E. K. Anderberg (1990)
10.2217/17435889.2.4.415
Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
T. Stinchcombe (2007)
10.1016/J.IJPHARM.2005.10.010
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Donald E. Owens (2006)
10.1211/002235702760345400
Characterization of a surface modified dry powder inhalation carrier prepared by “particle smoothing”
P. Young (2002)
10.1016/S0378-5173(00)00622-0
Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone.
C. Jacobs (2001)
10.1016/0378-5173(89)90069-0
The effect of particle size distribution on dissolution rate and oral absorption
R. J. Hintz (1989)



This paper is referenced by
10.1016/j.drudis.2018.01.016
Pharmaceutical nanocrystals: production by wet milling and applications.
M. Malamatari (2018)
10.1016/j.apsb.2018.07.011
Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications
Eknath Ahire (2018)
10.3109/10837450.2012.727001
Effect of fixed aqueous layer thickness of polymeric stabilizers on zeta potential and stability of aripiprazole nanosuspensions
A. Abdelbary (2013)
10.1016/j.addr.2011.10.009
Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
K. Kawakami (2012)
10.1081/e-ebpp-120050047
Excipients: Oral Drug Delivery
Kohsaku Kawakami (2015)
10.1517/17425247.2016.1142524
Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders
M. Malamatari (2016)
10.1021/jf201314u
Effect of organic-phase solvents on physicochemical properties and cellular uptake of astaxanthin nanodispersions.
N. Anarjan (2011)
10.1007/S12649-018-0528-Y
Evaluation the Effects of Ultrasonic Parameters on Simultaneously Extraction and Size Reduction of Lycopene from Tomato Processing Waste
N. Anarjan (2020)
10.1021/acs.molpharmaceut.8b00505
Formulation and Molecular Dynamics Simulations of a Fusidic Acid Nanosuspension for Simultaneously Enhancing Solubility and Antibacterial Activity.
Calvin Andeve Omolo (2018)
Design of advanced materials and nano delivery approaches for enhancing activity against Methicillin resistant Staphylococcus aureus.
C. Omolo (2018)
NANOSUSPENSIONS: A STRATEGY FOR IMPROVED BIOAVAILABILITY
S. Pattnaik (2013)
10.1016/j.ejpb.2019.05.024
Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.
D. Pade (2019)
10.1155/2015/216375
Nanosuspension technologies for delivery of poorly soluble drugs
R. Yadollahi (2015)
10.1016/j.actbio.2016.11.019
Critical review: Injectability of calcium phosphate pastes and cements.
R. O’Neill (2017)
Semantic Scholar Logo Some data provided by SemanticScholar